MedWatch

Novo chief on approval of prize asset: Probably the biggest achievement

The approval of Novo Nordisk’s GLP-1 analogue Ozempic is probably “the biggest” achievement for chief science officer (CSO) Mads Krogsgaard Thomsen during his 26 years in the Danish diabetes group. He is happy that the company now possesses the two best products of the drug class.

Foto: /ritzau/Peter Hove Olesen

Since 1991, Mads Krogsgaard Thomsen has been a part of Novo Nordisk’s R&D department and since the millennium, he has been responsible for the whole unit and involved in a range of new drug approvals.

However, FDA’s thumbs up for Novo Nordisk’s biggest hope, the GLP-1 analogue Ozempic (semaglutide), is clearly a highlight of his career.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier